Lycera is a biopharmaceutical company pioneering innovative approaches to the discovery and development of oral medicines for treating autoimmune diseases. The company is targeting novel pathways to develop new classes of selective, oral immunomodulators for the treatment of patients with diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease.